Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register

Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register

Background Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible for these trials differ significantly compared with real-...

Full description

Bibliographic Details
Main Authors: Marianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, Ole Hilberg, Sofie Lock-Johansson, Kjell Erik Julius Håkansson, Truls Sylvan Ingebrigtsen, Claus Rikard Johnsen, Linda Makowska Rasmussen, Anna von Bülow, Karin Dahl Assing, Johannes Martin Schmid, Charlotte Suppli Ulrik, Celeste Porsbjerg
Format: Article
Language:English
Published: European Respiratory Society 2022-10-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/8/4/00238-2022.full

Internet

http://openres.ersjournals.com/content/8/4/00238-2022.full

Similar Items